News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,800 Results
Type
Article (41318)
Company Profile (265)
Press Release (688199)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204831)
Career Advice (2031)
Deals (35577)
Drug Delivery (128)
Drug Development (81504)
Employer Resources (173)
FDA (16499)
Job Trends (14979)
News (346786)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (45)
Adcomms (26)
Allergies (170)
Alliances (49579)
ALS (207)
Alzheimer's disease (1778)
Antibody-drug conjugate (ADC) (434)
Approvals (16868)
Artificial intelligence (646)
Autoimmune disease (275)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (742)
Cancer (5730)
Cardiovascular disease (460)
Career advice (1723)
Career pathing (41)
CAR-T (319)
CDC (56)
Celiac Disease (3)
Cell therapy (863)
Cervical cancer (46)
Clinical research (70689)
Collaboration (2023)
Company closure (5)
Compensation (1372)
Complete response letters (77)
COVID-19 (2739)
CRISPR (107)
C-suite (1095)
Cystic fibrosis (150)
Data (7684)
Decentralized trials (3)
Denatured (27)
Depression (158)
Dermatology (82)
Diabetes (581)
Diagnostics (6908)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (313)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91798)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119242)
Executive appointments (1073)
FDA (20160)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1699)
Gene editing (230)
Generative AI (55)
Gene therapy (699)
GLP-1 (1047)
Government (4724)
Grass and pollen (6)
Guidances (407)
Healthcare (18981)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (284)
Immuno-oncology (88)
Indications (180)
Infectious disease (3075)
Inflammatory bowel disease (215)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16665)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (38)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (754)
Lymphoma (424)
Machine learning (59)
Management (59)
Manufacturing (1017)
MASH (183)
Medical device (13914)
Medtech (14023)
Mergers & acquisitions (20149)
Metabolic disorders (1478)
mRNA (198)
Multiple sclerosis (186)
NASH (17)
Neurodegenerative disease (406)
Neuropsychiatric disorders (104)
Neuroscience (3264)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (692)
Opinion (285)
Ovarian cancer (215)
Pain (250)
Pancreatic cancer (293)
Parkinson's disease (353)
Partnered (33)
Patents (590)
Patient recruitment (659)
Peanut (62)
People (59520)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22030)
Phase 2 (31144)
Phase 3 (23178)
Pipeline (8281)
Policy (311)
Postmarket research (2568)
Preclinical (9377)
Press Release (64)
Prostate cancer (292)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1051)
Real estate (5968)
Recruiting (70)
Regulatory (25319)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (176)
Series A (285)
Series B (210)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3637)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1085)
Venture capital (107)
Weight loss (444)
Women's health (122)
Worklife (20)
Date
Today (54)
Last 7 days (954)
Last 30 days (3215)
Last 365 days (30095)
2026 (11552)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (91)
Alaska (7)
Arizona (345)
Arkansas (14)
Asia (39623)
Australia (6496)
California (13043)
Canada (3711)
China (1310)
Colorado (558)
Connecticut (565)
Delaware (397)
Europe (85726)
Florida (1953)
Georgia (418)
Hawaii (3)
Idaho (62)
Illinois (1038)
India (88)
Indiana (593)
Iowa (23)
Japan (522)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1566)
Massachusetts (9295)
Michigan (358)
Minnesota (704)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3437)
New Mexico (29)
New York (3410)
North Carolina (1652)
North Dakota (8)
Northern California (6519)
Ohio (388)
Oklahoma (23)
Oregon (41)
Pennsylvania (2628)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5146)
Tennessee (209)
Texas (2065)
United States (46023)
Utah (391)
Vermont (1)
Virginia (311)
Washington D.C. (80)
Washington State (1047)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
729,800 Results for "uromedica inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial
Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI.
March 10, 2021
·
2 min read
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
Press Releases
Progyny, Inc. Announces First Quarter 2026 Results
May 8, 2026
·
28 min read
Press Releases
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
May 5, 2026
·
8 min read
Press Releases
Penumbra, Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
·
6 min read
Press Releases
DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
May 7, 2026
·
1 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
BioMidwest
Uromedica Announces New CPT-I codes for ProACT™ Adjustable Continence Therapy for Men
Uromedica, Inc. announces today that four new Category I CPT (Current Procedural Terminology) codes have been assigned to their FDA-approved product, ProACT™ Adjustable Continence Therapy for Men and will be effective January 1st, 2022.
November 19, 2021
·
2 min read
Press Releases
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
May 8, 2026
·
10 min read
Press Releases
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
May 8, 2026
·
18 min read
1 of 72,980
Next
